Trinity-Biotech-logo-white

Trinity Biotech plc

Trinity Biotech plc (Nasdaq: TRIB) is a global diagnostics company shaping the future of healthcare with innovative, data-driven solutions. Building on its established portfolio of diagnostic products and a strong revenue base, Trinity is expanding into high-growth markets with advanced technologies.

• Continuous Glucose Monitoring - Advanced Diabetes Care: At the core of Trinity’s strategic growth is its development of a next-generation continuous glucose monitoring (CGM) device, leveraging proprietary technology acquired from Waveform Technologies. This cutting-edge CGM device, currently in development, is engineered for ease of use, needle-free insertion, and reduced environmental impact. Learn more about Trinity’s CGM advancements at https://cgm.trinitybiotech.com.

In addition to CGM, Trinity Biotech has recently expanded into two other diagnostic fields through strategic acquisitions:

• Prostate Cancer Screening: Through the acquisition of EpiCapture, Trinity is developing advanced, non-invasive diagnostic tools for targeted monitoring of prostate cancer using epigenetic markers.
Preeclampsia Screening: Trinity’s acquisition of Metabolomics Diagnostics introduces pioneering tools for early detection of preeclampsia, advancing maternal health outcomes.

Trinity is poised to enhance care and drive growth in key markets worldwide through its commitment to innovation and focus on addressing large-scale healthcare challenges.

Nasdaq: TRIB
IR Website: https://www.trinitybiotech.com/investor-relations/
Nasdaq Profile: https://www.nasdaq.com/market-activity/stocks/trib
Headquarters: Ireland

Investor Contact: Eric Ribner, LifeSci Partners, LLC - investorrelations@trinitybiotech.com 

           

TALK TO MANAGEMENT

Trinity Biotech plc is always available to talk to current and potential investors. They're happy to answer any questions you may have and tell you what makes their story unique. Please fill out this form, and we will connect you shortly.

Press Releases & Media Coverage

Social Media Updates

Investor Presentation

Stock Chart (Intraday)

Stock Chart (Historical)

Stock Detail

Lead Drug Candidate: Crofelemer

How Crofelemer Works

Jaguar/Napo Product Portfolio – Crofelemer Pipeline

Videos – Jaguar Health: Improving Lives

Global Market Growth Opportunities

2023 Critical Activities to Unlock Jaguar Health's Value Potential

Commercial Rights and Partnerships

Jaguar and Magdalena Biosciences Collaboration

Financial Summary

Analyst Coverage

A Deep and Seasoned Leadership Team

SEC Filings

Financials

Risks & Disclosures

Trinity-Biotech-logo-white

The Trinity Biotech plc management and investor relations team are available to talk to current and potential investors. They're happy to answer your questions and tell you what makes their story unique. Please fill out this form, and we will connect you shortly.

• Directly hear the Trinity Biotech story
• Ask your questions
• Submit the form below, and someone will get in touch with you as soon as possible

Note: Company management or its representative can only discuss and disclose information that is already available in the public domain. They will do their best to clarify such information to the extent permitted by securities law and industry regulations.